Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence-Reference-Cited by-同舟云学术

Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence

Published:2009-12-11 Issue:4 Volume:27 Page:1286-1294
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Eissa Sanaa,Zohny Samir F.,Zekri Abdel-Rahman N.,El-Zayat Tarek Mostafa,Maher Amany M.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-009-9375-9.pdf

Reference26 articles.

1. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, et al. Epidemiology of urinary bladder cancer: from tumor development to patient’s death. World J Urol. 2007;25:285–95.

2. Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta. 2004;340:57–65.

3. Eissa S, Zohny SF, Swellam M, Mahmoud MH, El-Zayat TM, Salem AM. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer. Clin Biochem. 2008;41:1335–41.

4. Mao Y, Schwarzbauer JE. Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol. 2005;24:389–99.

5. Kirkali G, Tuzel E, Guler C, Gezer S, Kirkali Z. Significance of tissue laminin P(1) elastase and fibronectin levels in transitional cell carcinoma of the bladder. Eur Urol. 2001;39:292–9.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging;BMC Medicine;2023-04-05

2. Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?;Translational Andrology and Urology;2021-06

3. Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis;World Journal of Surgical Oncology;2018-03-21

4. The First Approved Gene Therapy Product for Cancer Ad-p53(Gendicine): 12 Years in the Clinic;Human Gene Therapy;2018-02

5. Identification of cancer prognosis-associated functional modules using differential co-expression networks;Oncotarget;2017-12-04